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Abstract
Objective To determine whether use of oral contraceptives is associated
with all cause and cause specific mortality.
Design Prospective cohort study.
Setting Nurses’ Health Study, data collected between 1976 and 2012.
Population 121 701 participants were prospectively followed for 36
years; lifetime oral contraceptive use was recorded biennially from 1976
to 1982.
Main outcome measures Overall and cause specific mortality, assessed
throughout follow-up until 2012. Cox proportional hazards models were
used to calculate the relative risks of all cause and cause specific
mortality associated with use of oral contraceptives.
Results In our population of 121 577 women with information on oral
contraceptive use, 63 626 were never users (52%) and 57 951 were
ever users (48%). After 3.6 million person years, we recorded 31 286
deaths. No association was observed between ever use of oral
contraceptives and all cause mortality. However, violent or accidental
deaths were more common among ever users (hazard ratio 1.20, 95%
confidence interval 1.04 to 1.37). Longer duration of use was more
strongly associated with certain causes of death, including premature
mortality due to breast cancer (test for trend P<0.0001) and decreased
mortality rates of ovarian cancer (P=0.002). Longer time since last use

was also associated with certain outcomes, including a positive
association with violent or accidental deaths (P=0.005).
Conclusions All cause mortality did not differ significantly between
women who had ever used oral contraceptives and never users. Oral
contraceptive use was associated with certain causes of death, including
increased rates of violent or accidental death and deaths due to breast
cancer, whereas deaths due to ovarian cancer were less common among
women who used oral contraceptives. These results pertain to earlier
oral contraceptive formulations with higher hormone doses rather than
the now more commonly used third and fourth generation formulations
with lower estrogen doses.

Introduction
Millions of women around the globe have used oral
contraceptives since their debut in 1957, and oral contraceptives
remain the most prescribed medication among US women aged
18-44.1 Oral contraceptives enable women to control their
reproduction and thereby govern other aspects of their lives,
such as career and family. Yet when oral contraceptives were
made available, although acute side effects began to become
apparent, no mechanism was in place to assess long term
consequences. This was one of the main reasons the Nurses’
Health Study was established.
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Numerous studies have weighed various health risks2 3 and
benefits4 5 of oral contraceptive use, but it is only now, 50 years
after oral contraceptives were first introduced, that the long term
risks of the first generation and second generation oral
contraceptives (defined by progestin type) can be studied. Since
oral contraceptive use can affect various health outcomes
through different mechanisms, mortality provides a uniquely
relevant estimate by combining different causes of death.
These long term risks can only be estimated using large cohort
studies with considerable follow-up.6-9 Researchers from both
the Oxford-Family Planning Association Contraceptive Study
and the Royal College of General Practitioners’ Oral
Contraception Study have examined this topic.6 7 Further
replication of these studies in other populations with even larger
sample sizes are, however, needed to confirm these findings,
especially among less common causes of death where more
statistical power may be needed to detect differences.

The reproducibility and validity of the data on oral
contraceptives were evaluated in a study among 215 randomly
selected participants from a similar study, the Nurses’ Health
Study II.11 We contrasted data from biennial questionnaires with
data from a subsequent telephone interview that used a
structured life events calendar. Agreement for ever use versus
never use was 99%, and the correlation for duration of use
calculated from the two sources was 0.94.

Mortality ascertainment

We examined the association of oral contraceptive use and
mortality after 36 years of follow-up in the Nurses’ Health
Study, which includes more than three times the number of
participants and, because the participants are older, 18 times
the total number of deaths as the Royal College of General
Practitioners’ Oral Contraception Study. Based on the previous
cohort findings, we hypothesized that total mortality would be
lower among women who ever used oral contraceptives. We
also expected total mortality to decrease further with longer
durations of oral contraceptive use and with more recent use.

We assessed deaths from all causes between the return of the
1976 questionnaire and the end of follow-up (September 2012)
using reports from families and by searching state mortality
files and the National Death Index.12 Based on a validation study,
we estimate that over 98% of deaths in our cohort have been
ascertained.13 The cause of death was determined by reviewing
the family reports, death certificates, and medical records.
Deaths were grouped into six broad categories, according to
ICD-8 (international classification of diseases, eighth revision)
codes: cancer (ICD-8 codes 140-209), cardiovascular diseases
(390-458), digestive diseases (520-577), violent/accidental
(800-999, E808-999), other diseases (all codes, except those
previously listed), and unconfirmed causes. Cause of death was
further subdivided (for example, breast cancer, cervical cancer,
uterine cancer) for additional analyses. These categories are
consistent with those used in other analyses of oral contraceptive
use and all cause mortality.7 14

Methods

Assessment of covariate information

Study population
The Nurses’ Health Study was established in 1976 when 121
701 married female registered nurses 30-55 years of age
completed a mailed questionnaire on their medical history and
lifestyle factors. As one of the original intents of establishing
the cohort was to examine the impact of oral contraceptive use
on risk of breast cancer, and it was believed in 1976 that
predominantly married women would be using oral
contraceptives, the study was restricted to women who had
previously in 1972 reported that they were married and were
without a personal history of breast cancer. Follow-up
questionnaires are sent biennially to participants, updating
information on other risk factors and newly diagnosed diseases.
Further details of the study have been described elsewhere.10
We excluded participants later determined ineligible for the
study (n=124) but no other exclusions were made, leaving 121
577 women in our baseline population.

Assessment of exposure
Information on oral contraceptive use, including starting and
stopping dates, was collected on every questionnaire from 1976
until 1982, at which point less than 1% of the cohort reported
oral contraceptive use. Participants reported all use of oral
contraceptives, which therefore included use for contraceptive
purposes and for other reasons, like endometriosis. We classified
all 121 577 women as never users or ever users, with no
minimum use necessary to qualify as an ever user. We also
calculated and updated the duration of use (≤1, >1 to <2, ≥2 to
<5, ≥5 to <10, ≥10 years) and time since last use (≤4, >4 to
<10, ≥10 to <15, ≥15 years). Owing to missing data on these
variables, we excluded 240 women from the analyses on
duration of use and 2745 from the analyses of time since last
use. For all regression analyses, we included dynamic use and
potential confounding covariates as time varying variables (see
supplementary file).
No commercial reuse: See rights and reprints http://www.bmj.com/permissions

We assessed information on covariates at baseline and during
each biennial follow-up. Participants were asked at baseline
about their date of birth and age at menarche. On the baseline
and subsequent questionnaires we assessed weight; height;
cigarette consumption; family medical history of breast, colon,
and ovarian cancer as well as of heart disease; parity; age at
first birth; hormone therapy use; duration of hormone therapy;
history of benign breast disease; age at menopause; tubal
ligation; and hysterectomy. Dietary intake, including alcohol,
and current marital status were first accessed in 1980, physical
activity in 1986, and race in 1992. We used the data from
subsequent questionnaires to update information on the time
varying covariates of calendar time, age, body mass index,
smoking, alcohol intake, physical activity, marital status,
hormone therapy use, duration of hormone therapy, history of
benign breast disease, tubal ligation, and hysterectomy. Some
of these covariates, such as hormone therapy use may have
occurred only after oral contraceptive use ended (see
supplementary file). Indicator variables were used for any
missing information on covariates.

We categorized covariates as body mass index (<21, 21-22.9,
23-24.9, 25-28.9, and ≥29); cigarette smoking status (never,
former, current); cigarette smoking amount and duration
(continuous pack years); age at menarche (<13, 13, 14, ≥15
years); alcohol intake (0, 0.1-9.9, 10-29.9, ≥30 g/d); physical
activity (<3, 3-8.9, 9-17.9, 18-26.9, ≥27 metabolic equivalents
of task (MET) h/wk); family history of breast, colon, and ovarian
cancer (each yes, no); parity (0, 1, 2, ≥3 children); age at first
birth (<24, 24-25, 26-29, ≥30 years); hormone therapy use
(never, former, current); duration of hormone therapy (0, 0.1-<5,
5-<10, ≥10 years); history of benign breast disease (yes, no);
tubal ligation (yes, no); hysterectomy without bilateral
oophorectomy (yes, no); family history of heart disease (yes,
no); and marital status (married or domestic partnership,
separated or divorced, widowed). The racial or ethnic
Subscribe: http://www.bmj.com/subscribe
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composition of the cohort is predominantly white, so we
categorized participants as white and non-white.

To increase efficiency we also examined risk factors previously
shown to be statistically associated with mortality in this
cohort15: body mass index at age 18 (per 7 kg/m2); weight change
since age 18 (per 23 kg), from the 1980 questionnaire; height
(per 15.2 cm); nuts (0, ≤1, ≥2 servings per week), from the 1986
questionnaire; polyunsaturated fat (per 3% energy), glycemic
load (per 41 units), dietary cholesterol (per 105 mg/1000 kcal),
and cereal fiber (per 4 g, energy adjusted), based on the average
values from 1980, 1984, and 1986 questionnaires; systolic blood
pressure (<120, 120-139, 140-149, 150-159, ≥160 mm Hg),
from the 1986 questionnaire; use of antihypertensive drugs (yes,
no), from the 1988 questionnaire; history of diabetes (yes, no),
from the 2008 questionnaire or previous; myocardial infarction
in a parent before age 60 (yes, no), from the 1988 questionnaire;
and time since menopause (per 13 years) from the 1986
questionnaire. We modeled each of these variables as they were
in the previously published model.15

Statistical analyses
We calculated person years of follow-up as the time from
completion of the baseline questionnaire to the end of follow-up
(September 2012), death, or loss to follow-up, whichever
occurred first. Cox proportional hazards models, stratified jointly
by age in months and calendar year of follow-up at the beginning
of each two year questionnaire cycle, were used to calculate the
relative risks (for example, hazard ratios) and 95% confidence
intervals of all cause and cause specific mortality associated
with oral contraceptive use for ever use or never use as well as
for duration of use and time since last use.

Owing to the complexity of cause specific mortality, we used
various adjustment strategies in our regression models. In model
1 we simultaneously adjusted for calendar time, age, body mass
index, smoking status, and race. In model 2 we adjusted for the
covariates in model 1 plus disease category risk factors. We
adjusted cancers for age at menarche, alcohol intake, and
physical activity, as well as a family history of breast, colon,
and ovarian cancer. Cardiovascular diseases were adjusted for
physical activity, alcohol intake, and family history of heart
disease. Digestive diseases were adjusted for alcohol intake.
We adjusted violent and accidental deaths for alcohol intake
and marital status. In model 3 we adjusted for the covariates in
model 2 plus mortality risk factors from a previous analysis
conducted in this cohort.15
The causes of death from model 3 that were statistically related
to oral contraceptive use, or even of borderline significance
(P<0.08), were then further analyzed by duration of use and
time since last use. We then analyzed these causes of death
using a 10 year lag analysis; therefore, we excluded mortality
cases during the 10 years between the last assessment of use
and the beginning of follow-up. In additional analyses (model
4), we made further adjustments for disease specific
confounders. For example, ovarian cancer analyses controlled
for parity, tubal ligation, and hysterectomy, whereas breast
cancer analyses controlled for parity, age at first birth, hormone
therapy use, duration of hormone therapy, and history of benign
breast disease.

All tests of statistical significance were two sided using P<0.05.
Trend tests were performed by modeling the medians of usage
categories as continuous variables. Analyses were conducted
with SAS software version 9.2.16

No commercial reuse: See rights and reprints http://www.bmj.com/permissions

Results
In our population of 121 577 women with information on oral
contraceptive use, 63 626 were never users (52.3%) and 57 951
were ever users (47.7%) at last report on oral contraceptive use.
Ever users reported a mean 4.1 years duration of use. Compared
with never users at the midpoint of follow-up in 1994, ever users
were more likely to have smoked, be younger at first birth, and
have used hormone therapy (table 1⇓).
After 36 years and 3.6 million person years of follow-up, we
observed 31 286 deaths (table 2⇓): 11 781 deaths from cancer,
6032 from cardiovascular disease, 855 from digestive disease,
1084 due to violence or accidents, 9212 from other diseases,
and 4381 due to unconfirmed causes. As effect estimates did
not vary greatly across the various adjustment models, results
provided are from the most complete model (either model 3 or
4, depending on the cause of death).

Overall, all cause mortality did not significantly differ between
women who had ever used oral contraceptives and those who
had never used oral contraceptives. However, violent or
accidental deaths were more common among ever users (hazard
ratio 1.20, 95% confidence interval 1.04 to 1.37), which was
driven by suicide (1.41, 1.05 to 1.87) compared with non-suicide
violent or accidental deaths (1.13, 0.97 to 1.32). The association
of oral contraceptive use with other causes of death, including
breast cancer (1.08, 0.98 to 1.18), ovarian cancer (0.86, 0.74 to
1.00), cerebrovascular disease (0.90, 0.80 to 1.01), and other
diseases (1.05, 1.00 to 1.10), was of borderline statistical
significance.

Longer duration of use (table 3⇓) was more strongly associated
with all cause mortality (test for trend P=0.02) as well as with
certain causes of death, including an increased rate for breast
cancer (P<0.0001) and a decreased rate for ovarian cancer
(P=0.002). Longer time since last use (table 4⇓) was associated
with increased all cause mortality (P=0.004) and certain
outcomes such as violent or accidental deaths (P=0.005). The
increased mortality from breast cancer was no longer significant
with 10-14 years or 15 years or more since last use. In a 10 year
lag analysis (table 5⇓), deaths from breast cancer were no longer
high, even with long durations of oral contraceptive use, but
the test for trend was still significant. When stratifying deaths
from breast cancer by hormone therapy use, oral contraceptive
use was most strongly associated with these deaths in never
users of hormone therapy. Violent or accidental deaths, including
suicides, were no longer statistically associated with oral
contraceptive use except with less than one year of use. Longer
use continued to be associated with decreased mortality due to
ovarian cancer (P=0.01).

Discussion
Ever use of oral contraceptives was not associated with all cause
mortality but it was associated with specific causes of death,
including an increased rate for deaths due to violence or
accidents and breast cancer as well as a decreased rate due to
ovarian cancer. Oral contraceptive use and mortality among
participants in the Nurses’ Health Study was previously
examined, including a 12 year follow-up.9 In our previous
analysis, no overall difference in mortality was seen in women
who had used oral contraceptives compared with those who had
never used oral contraceptives (hazard ratio 0.93, 95%
confidence interval 0.85 to 1.01).9 Our results did not materially
change with an additional 24 years of follow-up, but we were
able to examine more nuanced data on oral contraceptive use
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such as longer times since last use and to observe detailed
findings in cause specific deaths.

Comparisons to other studies
Our results for all cause mortality confirm similar earlier
findings from studies by the Royal College of General
Practitioners and Oxford-Family Planning Association. Early
reports from the Royal College of General Practitioners’ Oral
Contraception Study suggested a slight increase in all cause
mortality17 with oral contraceptive use, but subsequent analyses
reported no association or an inverse association.7 18 In the latest
Royal College of General Practitioners’ Oral Contraception
Study analyses, the authors examined a subcohort that had more
detailed information, and observed no association.19 Similarly,
the Oxford-Family Planning Association Contraceptive Study
reported a null finding, whereas a subsequent analysis identified
a marginal inverse association.6 20
Many of the cause specific results confirm previous findings in
other cohorts as well. Increased breast cancer rates have been
identified in previous reports,21-24 including the initial oral
contraceptive and mortality analysis in the Nurses’ Health Study,
which specifically reported increased mortality due to breast
cancer among current users.9 The inverse association of oral
contraceptive use and the incidence of various gynecological
cancers—for example, ovarian4 and uterine or endometrial25—is
well established. The Royal College of General Practitioners’
Oral Contraception Study also identified increased rates of
violent death among ever users. However, it is unlikely this is
a causal association given the lack of a biological mechanism
as well as inconsistent results in our other analyses, such as
duration of oral contraceptive use with violent death.
Our data revealed some new results on duration of oral
contraceptive use and time since last use. We observed increased
all cause mortality with longer durations of use and longer times
since last use, but the Royal College of General Practitioners’
and Oxford-Family Planning Association studies did not see
such trends.6 7 Increased deaths from breast cancer with longer
durations of use, which is in line with the most recent
meta-analysis,26 may explain the increasing all cause trend.
Similarly, the inverse association with gynecologic cancers
persists for many years after oral contraceptive use but seems
to dissipate after more than 15 years since last oral contraceptive
use. Using oral contraceptives for more than 15 years before
the last assessment in 1982 may also be a marker for use of the
earlier oral contraceptive formulations, which may have stronger
effects given the high estrogen dose.

Mechanisms
The mechanisms by which oral contraceptives may affect
various causes of death differ. With regard to cancer, estrogen
binds to cell receptors, which upregulate hormone responsive
genes and then promote DNA synthesis and cell proliferation.
If a cell has cancer causing mutations, it can more easily
proliferate and grow into a tumor.27 In addition, progestins can
bind to different steroid receptors, which can lead to cell
proliferation and cancer.28 The increased rates of violent or
accidental deaths could be confounded by increased rates of
intimate partner violence among ever users, since these women
are more likely to be in relationships where violence could take
place.29 Unfortunately, death records are not detailed enough to
discern such information and confirm this hypothesis. With
respect to suicides, an early analysis from the Royal College of
General Practitioners’ Oral Contraception Study found an
increased rate in ever users,30 whereas later analyses7 as well as
No commercial reuse: See rights and reprints http://www.bmj.com/permissions

analyses in the Oxford-Family Planning Association
Contraceptive Study18 reported null findings. The effect of oral
contraceptives on mental health, including depression and mood
changes, is not well understood but some of the most robust
studies actually suggest a small but protective effect.31-34
Compared with more common causes of death, such as
cardiovascular disease (n=6032), the absolute risk of having a
violent or accidental death (n=935), including by suicide
(n=234), is relatively low.

Strengths and limitations of this study
Previous literature has described the effect of oral contraceptive
use on acute events. Some of these adverse events seem to be
limited to current oral contraceptive users for diseases such as
venous thromboembolism, stroke, and myocardial infarction.35
Because our follow-up began in 1976, after many participants
had already initiated oral contraceptive use, we were not able
to observe all acute events; therefore our results may be prone
to some survivor bias (that is, a woman had to survive until
1976 to report her oral contraceptive use). These acute events
were rare, even with earlier, higher dosed formulations of oral
contraceptives, so this bias is unlikely to be strong.

The generalizability of our findings may be limited by the fact
that our population was homogenous for race and generation or
formulation of oral contraceptives. Most current oral
contraceptives contain lower estrogen doses (20-35 µg of ethinyl
estradiol) compared with oral contraceptives available in the
1950s through to the 80s (50-150 µg).36 37 Though the estrogen
dose is different from current oral contraceptives, there is more
similarity in the type of progestin. For example, first generation
and second generation oral contraceptives had debuted when
our participants were taking these drugs, so they were exposed
to both of these types of oral contraceptives, some of which are
still prescribed, in addition to more third generation and fourth
generation oral contraceptives. Older oral contraceptive
formulations may still be in use in resource poor countries as
well. It remains to be established whether newer low dose
formulations have similar effects as the oral contraceptives that
we studied. Nearly a dozen different types of progestins have
been used in oral contraceptives since the 1950s, but we did not
collect information on the different formulations in this cohort.
In future analyses, new oral contraceptives need to be evaluated,
especially because preliminary research indicates that some
progestin types, such as triphasic preparations with
levonorgestrel, may account for the increased risk of breast
cancer.38 Most oral contraceptive formulations now combine
estrogen and progestin, but in the 1950s and 60s, 20% of the
market was made up of sequential oral contraceptives, in which
each monthly cycle contained 16 estrogen pills followed by five
estrogen plus progesterone pills.39 Oral contraceptive use today
also differs in that long term use before pregnancy and extended
use are more common now, owing to factors such as changing
societal norms and pharmaceutical marketing. Finally, although
oral contraceptive formulations have changed since the
beginning of our study, our findings are still relevant especially
since so many women who took these older formulations are
still alive today.
Our study had several strengths. This is one of the largest cohorts
with the longest follow-up to examine lifetime oral contraceptive
use and mortality. The statistical power of our study enabled us
to examine various cause specific deaths such as from cervical
cancer, which is rare in this population. We were also able to
adjust for numerous covariates, including exposure to other
exogenous hormones such as hormone therapy use throughout
follow-up, though this did not significantly impact the results.
Subscribe: http://www.bmj.com/subscribe
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Hormone therapy use was reported more by ever users, so any
hormone therapy effect would be more common in the ever user
group. None the less, never users may have used other hormones
such as fertility drugs and hormone therapy, so continuing to
collect data in these large cohort studies will enable us to study
long term effects of different periods of sex steroid use among
all women, regardless of oral contraceptive history. The evolving
literature on use of both oral contraceptives and hormone therapy
will continue to illuminate the overall relation between sex
steroid therapy and mortality. Follow-up rates in our cohort are
high, with over 95% of participants being either actively
followed or having a recorded death. Mortality ascertainment
is over 98%, so loss to follow-up or underestimating deaths is
not likely to have biased our results. To identify potential
confounding, we controlled for several covariates. We also
conducted cause specific analyses with additional established
risk factors for various causes of death, but our results did not
appreciably change. Sensitivity analyses in other studies9 39 did
not reveal important biases, which is reassuring and suggests
that we are unlikely to have missed any major associations or
confounding factors.

Conclusions
Overall, ever oral contraceptive use had no association with
overall mortality but had diverse associations with cause specific
mortality, including increased mortality from breast cancer and
decreased mortality from ovarian cancer. Women who took first
generation and second generation oral contraceptives through
the early 1980s can be reassured that this is unlikely to impact
their mortality rate. These results primarily pertain to earlier
formulations of oral contraceptives, though some of these (for
example, second generation oral contraceptives, which include
progestins such as levonorgestrel and norgestrel) are still
commonly used but now with lower estrogen doses. However,
these results may not apply to the now more commonly used
third generation and fourth generation formulations.

In light of mortality analyses, the benefits of using oral
contraceptives for both pregnancy prevention and
non-contraceptive reasons should not be forgotten. Oral
contraceptives help to ameliorate countless ailments, including
dysmenorrhea, fibroid related symptoms, acne, and premenstrual
dysphoric disorder.40 Oral contraceptive use also drastically
reduces maternal mortality41 in several ways, including lowering
the chance of pregnancy and its complications as well as
reducing the risk of having an unsafe abortion. Even the first
generation oral contraceptives had specific benefits, including
a decrease in ovarian cysts and benign ovarian tumors.42-46 With
new contraceptive technologies, such as the vaginal ring and
patch, as well as increasing use of intrauterine devices,47 it is
imperative to understand the impact of exogenous sex steroids
in contraceptives so that women can make informed decisions.
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Tables
Table 1| Age standardized characteristics of ever and never users of oral contraceptives among 121 577 participants in the Nurses’ Health

Study at midpoint of follow-up (1994), 1976-2012. Values are percentages (number of participants) unless stated otherwise
Characteristics

Never users (n=63 626) Ever users (n=57 951)

Base model (model 1)
Mean (SD) age (years)

61.2 (7.1)

60.8 (7.1)

Mean (SD) BMI (kg/m²)

26.6 (5.1)

26.3 (5.0)

Mean (SD) smoking amount and duration (pack years)

11.9 (19.0)

13.1 (19.8)

Never

43 (27 423)

39 (22 775)

Former

36 (23 096)

39 (22 717)

Current

12 (7762)

13 (7592)

77 (49 183)

80 (46 477)

8 (5154)

7 (4230)

12.4 (1.8)

12.5 (1.8)

Smoking status*:

Race*:
White
Non-white
Disease category risk factors (model 2)
Mean (SD) age at menarche (years)
Mean (SD) alcohol intake (g/day)
Mean (SD) physical activity (MET h/wk)

4.5 (8.6)

5.5 (9.7)

19.5 (25.0)

19.6 (24.4)

56 (35 821)

59 (34 365)

Marital status*†:
Married or in domestic partnership
Separated or divorced

5 (3372)

7 (4172)

Widowed

11 (7126)

10 (5853)

Breast cancer

13 (8335)

14 (8345)

Colon cancer

12 (7826)

12 (7070)

Ovarian cancer

2 (1336)

2 (1217)

77 (49 247)

79 (45 955)

21.4 (2.7)

21.2 (2.7)

Family history:

Heart disease
Mortality risk factors (model 3)
Mean (SD) BMI at age 18 (kg/m²)
Mean (SD) weight change since age 18 (kg)

7.1 (12.3)

6.7 (11.8)

Mean (SD) height (cm)

163.8 (6.1)

163.8 (6.1)

0.7 (1.9)

0.7 (2.0)

Mean (SD) nut consumption (servings/wk)‡
Mean (SD) polyunsaturated fat (% energy)‡

5.7 (1.1)

5.7 (1.1)

Mean (SD) glycemic load (GL units)‡

100.0 (17.0)

98.8 (16.7)

Mean (SD) dietary cholesterol (mg/1000 kJ per day)‡

686.2 (188.3)

690.4 (188.3)

Mean (SD) cereal fiber (g/d energy adjusted)‡

4.2 (1.9)

4.3 (2.0)

Mean (SD) systolic blood pressure (mm Hg)*

130.0 (15.0)

129.0 (15.0)

Use of antihypertensive drugs

22 (14 125)

24 (14 082)

History of diabetes
Parental myocardial infarction before age 60
Mean (SD) time since menopause (years)

7 (4517)

7 (4172)

17 (10 944)

18 (10 605)

11.6 (8.6)

11.0 (7.9)

Disease risk factors (model 4)
Mean (SD) age at first birth (years)†

32.5 (22.0)

29.8 (18.1)

Mean (SD) parity†

2.9 (1.7)

3.1 (1.6)

Mean (SD) duration of hormone therapy (years)

3.0 (5.4)

3.8 (5.5)

Hormone therapy use*:
Premenopausal
Never

12 (7699)

11 (6433)

26 (16 670)

20 (11 706)
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Table 1 (continued)
Characteristics

Never users (n=63 626) Ever users (n=57 951)

Former

15 (9671)

17 (9910)

Current

28 (18 006)

36 (20 978)

15 (9671)

20 (11 764)

Tubal ligation
Hysterectomy without bilateral oophorectomy
History of benign breast disease

13 (8462)

15 (8924)

42 (26 850)

44 (25 672)

BMI=body mass index; MET=metabolic equivalent of task.
*May not add to 100% owing to missing data.
†Assessed in 1996.
‡Average of dietary values through 1994.
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Table 2| Total and cause specific mortality in ever and never users of oral contraceptives among 121 577 participants in the Nurses’ Health

Study, 1976-2012
Cause of death

Hazard ratio (95% CI)
ICD-8 codes

Never users

Ever users

Model 1*

Model 2+disease
category risk factors†

Model 3+mortality risk
factors‡

000 to 999, all E
codes

20 646

10 640

1.01 (0.98 to 1.03)

—

1.02 (0.99 to 1.04)

All cancers:

140 to 209

7420

4361

1.00 (0.96 to 1.04)

1.01 (0.97 to 1.05)

1.01 (0.97 to 1.05)

Large bowel and
rectum

153 to 154

693

361

0.95 (0.83 to 1.09)

0.97 (0.84 to 1.11)

0.97 (0.84 to 1.11)

Gallbladder/liver

All causes

155 to 156

158

90

0.96 (0.73 to 1.28)

0.98 (0.74 to 1.30)

0.98 (0.74 to 1.30)

Lung

162

1637

1007

1.05 (0.96 to 1.14)

1.05 (0.96 to 1.14)

1.05 (0.97 to 1.14)

Melanoma

172

111

58

0.77 (0.55 to 1.09)

0.76 (0.54 to 1.07)

0.76 (0.54 to 1.08)

Breast

174

1387

908

1.09 (0.99 to 1.20)

1.09 (0.99 to 1.20)

1.08 (0.98 to 1.18)

Cervical

180

30

18

1.00 (0.52 to 1.92)

1.01 (0.52 to 1.96)

1.04 (0.54 to 2.02)

Uterine/endometrial

182

224

111

0.79 (0.61 to 1.02)

0.81 (0.63 to 1.04)

0.81 (0.63 to 1.03)

Ovarian

183

538

314

0.87 (0.75 to 1.02)

0.88 (0.76 to 1.02)

0.86 (0.74 to 1.00)

CNS-pituitary

191, 194

214

141

1.03 (0.81 to 1.30)

1.04 (0.82 to 1.31)

1.05 (0.83 to 1.33)

Site unknown

199

443

231

0.95 (0.80 to 1.12)

0.95 (0.80 to 1.13)

0.94 (0.79 to 1.12)

Other cancers

140 to 209, except
above

1985

1122

1.01 (0.93 to 1.09)

1.02 (0.94 to 1.11)

1.03 (0.95 to 1.11)

All cardiovascular
diseases:

390 to 458

4257

1775

0.98 (0.92 to 1.04)

1.00 (0.94 to 1.06)

1.00 (0.94 to 1.06)

Ischemic heart disease

410 to 414

1857

789

1.02 (0.94 to 1.12)

1.04 (0.95 to 1.14)

1.04 (0.95 to 1.14)

Other heart

420 to 429

629

259

0.96 (0.81 to 1.12)

0.97 (0.83 to 1.13)

0.96 (0.82 to 1.12)

430 to 438

1196

445

0.89 (0.79 to 1.00)

0.90 (0.80 to 1.01)

0.90 (0.80 to 1.01)

Thromboembolic

444 to 445, 451 to
453

104

52

1.05 (0.74 to 1.50)

1.07 (0.75 to 1.52)

1.06 (0.74 to 1.51)

Other circulatory

390 to 409, 440 to
458, except above

471

230

1.06 (0.90 to 1.26)

1.08 (0.91 to 1.28)

1.10 (0.93 to 1.31)

520 to 577

549

306

1.07 (0.92 to 1.24)

1.07 (0.91 to 1.24)

1.10 (0.95 to 1.28)

570 to 573

226

153

1.14 (0.91 to 1.42)

1.12 (0.90 to 1.41)

1.15 (0.91 to 1.44)

800 to 999, E808-999

640

444

1.20 (1.05 to 1.37)

1.18 (1.03 to 1.35)

1.20 (1.04 to 1.37)

E950-959

111

130

1.43 (1.08 to 1.90)

1.42 (1.07 to 1.88)

1.41 (1.05 to 1.87)

All codes, except
above

6182

3030

1.03 (0.98 to 1.08)

—

1.05 (1.00 to 1.10)

NA

2916

1465

0.95 (0.89 to 1.02)

—

0.98 (0.91 to 1.04)

Cerebrovascular
disease

All digestive diseases:
Liver disease
Violence/accidents
Suicide
Other diseases
Unconfirmed
NA=not available.

*Adjusts for calendar time, age, body mass index, race, smoking status, and smoking amount/duration, with never users as reference.
†Adjusts for variables in model 1 and further adjusts for disease category risk factors. Cancers are adjusted for age at menarche, alcohol intake, physical activity,
and family history of breast, colon, and ovarian cancer. Cardiovascular diseases are adjusted for alcohol intake, physical activity, and family history of heart disease.
Digestive diseases are adjusted for alcohol intake. Violent/accidental deaths are adjusted for alcohol intake and marital status.
‡Adjusts for variables in model 2 and further adjusts for mortality risk factors, including body mass index at age 18, weight change since age 18, height, alcohol
intake, physical activity, nut consumption, polyunsaturated fat, glycemic load, dietary cholesterol, cereal fiber, systolic blood pressure, use of antihypertensive
drugs, personal history of diabetes, parental myocardial infarction before age 60, and time since menopause.
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Table 3| Hazard ratios (95% confidence intervals) of total and cause specific mortality by duration of oral contraceptive use (years) compared

with never users among 121 337 participants in the Nurses’ Health Study, 1976-2012

Duration of oral contraceptive use (years)
Cause of death

≤1

>1 to <2

≥2 to <5

≥5 to <10

≥10

All causes* (n=31 237)

1.01 (0.97 to 1.05)

1.01 (0.94 to 1.08)

1.02 (0.97 to 1.06)

1.05 (1.00 to 1.09)

1.05 (0.99 to 1.12)

P for trend
0.02

Breast cancer† (n=2295)

1.06 (0.93 to 1.22)

1.05 (0.84 to 1.33)

1.03 (0.89 to 1.21)

1.20 (1.03 to 1.40)

1.27 (1.03 to 1.56)

0.003

Breast cancer, further
adjusted‡

1.05 (0.91 to 1.21)

1.06 (0.84 to 1.33)

1.05 (0.90 to 1.23)

1.26 (1.09 to 1.46)

1.39 (1.13 to 1.71)

<0.0001

Ovarian cancer† (n=851)

0.89 (0.70 to 1.12)

0.96 (0.67 to 1.39)

0.99 (0.78 to 1.25)

0.70 (0.53 to 0.92)

0.60 (0.39 to 0.92)

0.002

Ovarian cancer, further
adjusted§

0.89 (0.71 to 1.12)

0.96 (0.67 to 1.39)

0.98 (0.77 to 1.25)

0.69 (0.53 to 0.92)

0.60 (0.40 to 0.93)

0.002

Cerebrovascular
disease¶ (n=1639)

0.73 (0.60 to 0.90)

0.89 (0.63 to 1.25)

0.89 (0.72 to 1.11)

0.98 (0.79 to 1.19)

1.21 (0.94 to 1.56)

0.26

Violence/accidents**
(n=1083)

1.35 (1.12 to 1.64)

0.81 (0.55 to 1.19)

1.12 (0.90 to 1.40)

0.94 (0.74 to 1.20)

1.13 (0.83 to 1.55)

0.94

Suicide** (n=240)

1.36 (0.91 to 2.02)

0.99 (0.51 to 1.93)

1.55 (1.05 to 2.30)

0.84 (0.51 to 1.39)

1.83 (1.07 to 3.15)

0.26

Other diseases* (n=9195)

1.05 (0.98 to 1.14)

1.02 (0.89 to 1.16)

1.04 (0.96 to 1.13)

1.05 (0.97 to 1.14)

1.11 (1.00 to 1.24)

0.04

*Adjusts for model 3 variables: base model+mortality risk factors.
†Adjusts for model 3 variables: base model+cancer risk factors+mortality risk factors.
‡Adjusts for model 4 variables: base model+cancer risk factors+mortality risk factors+breast cancer risk factors (parity, age at first birth, hormone therapy use,
duration of hormone therapy, and history of benign breast disease).
§Adjusts for model 4 variables: base model+cancer risk factors+mortality risk factors+ovarian cancer risk factors (parity, tubal ligation, and hysterectomy).
¶Adjusts for model 3 variables: sociodemographics+cardiovascular risk factors+mortality risk factors.
**Adjusts for model 3 variables: sociodemographics+violent/accident death risk factors+mortality risk factors.
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Table 4| Hazard ratios (95% confidence intervals) of total and cause specific mortality by time since last oral contraceptive use (years)

compared with never users among 118 832 Nurses’ Health Study participants, 1976-2012

Time since last oral contraceptive use (years)
Cause of death

≤4

>4 to <10

≥10 to <15

≥15

P for trend

All causes* (n=30 541)

0.97 (0.92 to 1.02)

1.02 (0.98 to 1.06)

1.04 (1.00 to 1.08)

1.06 (1.01 to 1.10)

0.004

Breast cancer† (n=2253)

1.01 (0.84 to 1.21)

1.19 (1.04 to 1.37)

1.10 (0.96 to 1.26)

1.09 (0.93 to 1.29)

0.05

Breast cancer, further
adjusted‡

1.07 (0.89 to 1.28)

1.23 (1.07 to 1.42)

1.13 (0.98 to 1.29)

1.09 (0.92 to 1.28)

0.04

Ovarian cancer† (n=827)

0.76 (0.56 to 1.04)

0.61 (0.46 to 0.80)

0.97 (0.78 to 1.20)

1.04 (0.81 to 1.33)

0.69

Ovarian cancer, further
adjusted§

0.77 (0.56 to 1.05)

0.61 (0.47 to 0.81)

0.97 (0.78 to 1.20)

1.03 (0.81 to 1.33)

0.69

Cerebrovascular disease¶
(n=1604)

0.99 (0.77 to 1.27)

0.93 (0.76 to 1.13)

0.91 (0.76 to 1.10)

0.82 (0.66 to 1.02)

0.05

Violence/accidents**
(n=1044)

1.11 (0.85 to 1.44)

1.09 (0.88 to 1.35)

1.18 (0.97 to 1.44)

1.37 (1.09 to 1.71)

0.005

Suicide** (n=231)

1.31 (0.81 to 2.12)

1.33 (0.87 to 2.01)

1.44 (0.97 to 2.13)

1.68 (1.06 to 2.66)

0.01

Other diseases* (n=8979)

1.02 (0.92 to 1.12)

1.05 (0.97 to 1.14)

1.05 (0.98 to 1.14)

1.09 (1.00 to 1.18)

0.02

*Adjusts for model 3 variables: base model+mortality risk factors.
†Adjusts for model 3 variables: base model+cancer risk factors+mortality risk factors.
‡Adjusts for model 4 variables: base model+cancer risk factors+mortality risk factors+breast cancer risk factors (parity, age at first birth, hormone therapy use,
duration of hormone therapy, and history of benign breast disease).
§Adjusts for model 4 variables: base model+cancer risk factors+mortality risk factors+ovarian cancer risk factors (parity, tubal ligation, and hysterectomy).
¶Adjusts for model 3 variables: sociodemographics+cardiovascular risk factors+mortality risk factors.
**Adjusts for model 3 variables: sociodemographics+violent/accident death risk factors+mortality risk factors.
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Table 5| Ten year lag analysis of total and cause specific mortality by duration of oral contraceptive use (years) compared with never users

among 117 506 participants in the Nurses’ Health Study, 1986-2012; hazard ratios (95% confidence intervals)
Duration of oral contraceptive use (years)
Cause of death

≤1

>1 to <2

≥2 to <5

≥5 to <10

≥10

P for trend

All causes* (n=28 200)

1.02 (0.98 to 1.06)

1.01 (0.94 to 1.09)

1.01 (0.97 to 1.06)

1.03 (0.99 to 1.08)

1.04 (0.98 to 1.11)

0.11

Breast cancer† (n=1749)

0.98 (0.84 to 1.16)

1.02 (0.79 to 1.31)

0.93 (0.78 to 1.11)

1.06 (0.89 to 1.25)

1.12 (0.88 to 1.42)

0.34

Breast cancer, further
adjusted‡

0.98 (0.84 to 1.16)

1.05 (0.82 to 1.36)

0.97 (0.81 to 1.16)

1.13 (0.95 to 1.35)

1.22 (0.96 to 1.55)

0.04

Ovarian cancer† (n=700)

0.86 (0.67 to 1.11)

0.89 (0.59 to 1.33)

0.97 (0.75 to 1.25)

0.68 (0.50 to 0.92)

0.68 (0.45 to 1.04)

0.008

Ovarian cancer, further
adjusted§

0.85 (0.66 to 1.09)

0.87 (0.58 to 1.31)

0.95 (0.73 to 1.23)

0.68 (0.50 to 0.91)

0.70 (0.45 to 1.06)

0.01

Cerebrovascular
disease¶ (n=1492)

0.74 (0.60 to 0.91)

0.87 (0.60 to 1.25)

0.93 (0.74 to 1.16)

0.91 (0.72 to 1.13)

1.09 (0.83 to 1.45)

0.89

Violence/accidents**
(n=840)

1.38 (1.12 to 1.71)

0.78 (0.50 to 1.22)

1.13 (0.88 to 1.45)

0.86 (0.64 to 1.14)

0.87 (0.58 to 1.29)

0.15

Suicide** (n=140)

1.18 (0.69 to 2.00)

1.12 (0.50 to 2.52)

1.60 (0.97 to 2.64)

0.78 (0.40 to 1.52)

1.58 (0.77 to 3.24)

0.60

Other diseases* (n=8562)

1.07 (0.99 to 1.15)

1.01 (0.88 to 1.16)

1.04 (0.95 to 1.13)

1.06 (0.97 to 1.16)

1.11 (0.99 to 1.25)

0.05

*Adjusts for model 3 variables: base model+mortality risk factors.
†Adjusts for model 3 variables: base model+cancer risk factors+mortality risk factors.
‡Adjusts for model 4 variables: base model+cancer risk factors+mortality risk factors+breast cancer risk factors (parity, age at first birth, hormone therapy use,
hormone therapy duration, and history of benign breast disease).
§Adjusts for model 4 variables: base model+cancer risk factors+mortality risk factors+ovarian cancer risk factors (parity, tubal ligation, and hysterectomy).
¶Adjusts for model 3 variables: sociodemographics+cardiovascular risk factors+mortality risk factors.
**Adjusts for model 3 variables: sociodemographics+violent/accident death risk factors+mortality risk factors.
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